Sightsavers Ireland awarded Triple Lock charity status

May 2023

Sightsavers Ireland has been awarded Triple Lock status for high standards by Charities Institute Ireland.

Triple Lock status is awarded to charities that uphold the highest standards in transparent reporting, ethical fundraising and strong governance. It is the gold standard for Irish charities to assure the public, donors, corporates, trusts and foundations that they are trustworthy.

To achieve the award, Sightsavers Ireland has adopted the Charities Regulator’s fundraising guidelines and implemented controls to ensure that fundraising practices are fully in line with them. Sightsavers Ireland also publishes annual financial statements and reports in compliance with the Charity SORP accounting standard and has fully implemented the Charities Governance Code.

Sightsavers Ireland is committed to keeping policies and procedures under constant review to maintain Triple Lock status.

Charities Institute Ireland triple lock logo.

Read all our latest news stories

News from Sightsavers
Two men shake hands during an awards ceremony. One man hands the other man an engraved glass award.

Sightsavers’ Abdulai Dumbuya wins award for inclusive education work

Abdulai has been recognised at this year’s Presidential National Best Teachers Awards in Sierra Leone for his work to make education systems more inclusive of children with disabilities.

October 2025
A boy wearing glasses smiling. Behind him, a girl wearing a hijab is beaming.

Sightsavers receives funding from Bloomberg Philanthropies to tackle visual impairment

Sightsavers has joined a US$75 million initiative to boost eye health services and help address the global vision crisis.

September 2025
Nar, who had successful treatment for trachoma, sits outside with her two grandchildren. They are all smiling.

Senegal reaches historic milestone by eliminating trachoma

Thanks to support from Sightsavers and other organisations, millions of people in Senegal are no longer at risk from losing their sight to the eye disease.

July 2025